<unk>  has demonstrated significant efficacy and safety in patients with idiopathic multicentric Castleman disease. Treatment results with<unk>  in B-cell non-Hodgkin's lymphoma are inferior to those obtained in multicentric Castleman disease.<unk>  has also been evaluated in the treatment ovarian cancer, however the efficacy for this cancer is debatable. In addition,<unk>  has been evaluated for multiple myeloma, but there was an insignificant increase in response rates.
Siltuximab
Dinutuximab
Margetuximab
Isatuximab
Loncastuximab tesirine
Alirocumab
Blinatumomab
Daratumumab